After hitting big in multiple myeloma, J&J, Genmab now have a new 'breakthrough' in NSCLC to boast about
Lending credence to J&J and Genmab’s promise that their alliance can produce something big outside of multiple myeloma, the FDA has granted breakthrough therapy designation for JNJ-6372 — a bispecific against metastatic non-small cell lung cancer.
The early-stage drug hits EGFR (epidermal growth factor receptor) and MET (mesenchymal epithelial transition factor) mutations and amplifications. Specifically, an approval could make it the first targeted therapy for patients who have EGFR exon 20 insertion mutations.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.